ALLHAT Do the SBP differences between the lisinopril and chlorthalidone arms explain the differences in CVD outcomes?

Slides:

Advertisements

Similar presentations

ALLHAT New Research Opportunities.

Advertisements

11/2/ Implications of ASCOT Results for ALLHAT Conclusions ALLHAT.

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)

Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.

1 SECOND AUSTRALIAN NATIONAL BLOOD PRESSURE STUDY (ANBP-2) Enalapril/ACEI vs. HCTZ, n = 6,083 Randomized, open-label (blinded endpoint review) All CV events.

UKPDS Paper 36 Slides © University of Oxford Diabetes Trials Unit UKPDS slides are copyright and remain the property of the University of Oxford Diabetes.

Heart Failure With Preserved And Impaired Systolic Left Ventricular Function In ALLHAT JB Kostis, B Davis, L Simpson, H Black, W Cushman, P Einhorn, M.

U.S. Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute The Antihypertensive and Lipid-Lowering.

1 The JNC 7 recommendations for initial or combination drug therapy are based on sound scientific evidence.

Did Type of Prior Antihypertensive Therapy Influence the Heart Failure Results in ALLHAT? Richard Grimm, Barry Davis, Linda Piller, Karen Margolis, Joshua.

Results of Monotherapy in ALLHAT: On-treatment Analyses ALLHAT Outcomes for participants who received no step-up drugs.

1 Presenter Disclosure Information FINANCIAL DISCLOSURE: DSMB’s: Merck, Takeda Barry R. Davis, MD, PhD Clinical Outcomes in Participants with Dysmetabolic.

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.

1 Setting the Record Straight ALLHAT. 2 Major ALLHAT Findings CHD risk not improved for any of the 3 newer agents compared with chlorthalidone Total mortality.

Is It the Achieved Blood Pressure or Specific Medications that Make a Difference in Outcome, or Is the Question Moot? William C. Cushman, MD Professor,

1 ATRIAL FIBRILLATION AT BASELINE AND DURING FOLLOW-UP in The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial November 9, 2003.

1 U.S. Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute Major Outcomes in High Risk Hypertensive.

1 Antihypertensive Trial Outcome Differences: Diuretic vs. Calcium Channel Blocker Compared to participants assigned to the diuretic, those assigned to.

1 Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial ALLHAT Davis.

1 Can One Evaluate An Outcomes Claim Based On An Active Controlled Study? Pfizer Response Cardiovascular and Renal Drugs Advisory Committee Rockville,

1 Review of the Design and Initial Findings for Pre-specified Outcomes and Subgroups Paul K. Whelton, M.D., M.Sc. Loyola University Medical Center Maywood,

Heart Failure (HF) Findings: Are They Real? Stanley S. Franklin, MD, FACP, FACC Clinical Professor of Medicine University of California at Irvine Associate.

HvC Comparative Effectiveness Project Groups 5 and 6

VBWG Predictor of CV Events and Mortality in Postmenopausal Women: Leukocyte Count.

ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:

7/27/2006 Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* * Wright JT, Dunn JK, Cutler JA.

Polypill x Aspirin Project Groups 3 and 4

Objective: To asses the efficacy of hydrochlorothiazide on 24-h blood pressure (BP) control.Methods: Review of all the randomized trials that assessed.

ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)

1 ALLHAT Antihypertensive Trial Results by Baseline Diabetic Status January 28, 2004.

6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.

Cardiovascular Outcomes in Hypertensives with CHD Randomized to Amlodipine versus Lisinopril in ALLHAT Frans Leenen MD, PhD, Chuke Nwachuku MA, MPH, Dr.

From: Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study Ann Intern Med. 2015;163(5):

Hazard ratio (& 95% CI) for 20 mmHg lower usual systolic BP

Blood Pressure and Lipid Trials: Rationale, Importance and Design

What should the Systolic BP treatment goal be in patients with CKD?

Nephrology Journal Club The SPRINT Trial Parker Gregg

The ACCORD Trial: Review of Design and Results

The SPRINT Research Group

US cost-effectiveness of simvastatin in 20,536 people at different levels of vascular disease risk: randomised placebo-controlled trial UK Medical Research.

Health and Human Services National Heart, Lung, and Blood Institute

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Vanguard Phase Results for the Blood Pressure Component

Jan B. Pietzsch1, Benjamin P. Geisler1, Murray D. Esler 2

ALLHAT ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status.

Should SPRINT change our practice?

Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck

Copyright © 2007 American Medical Association. All rights reserved.

United States Preventive Services Task Force: Recommendations for ABPM

HDL cholesterol and cardiovascular risk Epidemiological evidence

HDL cholesterol and cardiovascular risk

Teaching Tool: Blood Pressure Classification

Systolic Blood Pressure Intervention Trial (SPRINT)

Progress and Promise in RAAS Blockade

ALLHAT: What Outcomes Would Have Been Expected?

Determinants of new onset diabetes among hypertensive patients randomised in the ASCOT-BPLA Trial Dr Ajay K Gupta International Centre for Circulatory.

Andrea Ganna, PhD, Prof Erik Ingelsson, MD The Lancet

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)

Health and Human Services National Heart, Lung, and Blood Institute

Lowering of SBP by 20 mm Hg Reduces Cardiovascular Risk by Half

Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies

Originally presented by Drs. Daniel Levy, Richard H. Grimm, Steven E

These slides are based on a presentation at the 3rd International Forum on Angiotensin II Receptor Antagonists at Monte Carlo, Monaco January which took.

Adjusted relative risk for developing end-stage renal disease (ESRD) associated with blood-pressure level BP level (mm Hg) Adjusted relative risk 95%

Post-Heart Failure Mortality

The following slides highlight a report by Dr

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Volume 73, Issue 8, Pages (April 2008)

Simvastatin in Patients With Prior Cerebrovascular Disease: HPS

Presentation transcript:

ALLHAT Do the SBP differences between the lisinopril and chlorthalidone arms explain the differences in CVD outcomes?

BP differences: lisinopril versus chlorthalidone ALLHAT Mean follow-up SBP for L vs. C 2 mm Hg higher – all participants 4 mm Hg higher – Black participants Adjustment for follow-up SBP/DBP as time-dependent covariates in a Cox regression model slightly reduced the relative risks but they remained statistically significant Stroke (1.15  1.12) & HF (1.20  1.17), overall Stroke (1.40  1.35) & HF (1.32  1.26), for Blacks

BP differences: lisinopril versus chlorthalidone (continued) ALLHAT Prospective observational studies* predict that 2 mm Hg difference → 9% higher stroke mortality & 6% higher HF mortality, versus 15 & 19% higher risk (fatal + nonfatal events) observed in ALLHAT Based on same data, 4 mm Hg difference in blacks would predict 19% higher stroke mortality & 14% higher HF mortality, versus 40% & 32% higher risk (fatal + nonfatal events) in ALLHAT *Prospective studies collaboration. Lancet 2002;360:1903. In MRFIT screenees 12 year follow-up, BP association with stroke mortality similar in black and white middle-aged men (Stamler J, Stamler R, Neaton J. Arch Intern Med 1993;153:598.)

BP differences: lisinopril versus chlorthalidone (continued) ALLHAT Although application of epidemiologic adjustments and extrapolations have limitations, seems unlikely that BP differences explain total effects. ALLHAT will also conduct a meta-regression analysis of BP and CVD endpoints, with clinics (1 or more) as unit of analysis. This will reduce BP measurement error.

BP differences: Future analyses ALLHAT Divide ALLHAT into a number of large or mega-clinics, i.e. small clinics combined into mega-clinics. Within each mega-clinic compute a) mean follow-up SBP difference between diuretic and other treatment arm, and b) log hazard ratio (for a given endpoint) using Cox model. Do a weighted regression of log hazard ratios against follow-up SBP differences. A markedly non-zero intercept indicates drug treatment effect is not entirely explained by SBP differences.